Search

10X Genomics Inc (Class A)

Затворен

СекторЗдравеопазване

72.25 -2.07

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

71.12

Максимум

77.66

Ключови измерители

By Trading Economics

Приходи

-4.5M

-18M

Продажби

193K

151M

EPS

-0.14

Марж на печалбата

-11.872

Служители

1,178

EBITDA

-18M

-19M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

-28.44% downside

Дивиденти

By Acuity

Следващи печалби

5.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

3.2B

9.1B

Предишно отваряне

74.32

Предишно затваряне

72.25

Настроения в новините

By Acuity

50%

50%

129 / 339 Класиране в Healthcare

10X Genomics Inc (Class A) Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.09.2026 г., 23:02 ч. UTC

10X Genomics Inc shares are higher in after-market trading, reflecting overall positive market sentiment despite recent declines in manufacturing and rising crude oil inventories.

14.09.2026 г., 23:06 ч. UTC

10X Genomics Inc. shares are lower in after-market trading, aligning with a broader U.S. market decline amid rising crude oil prices due to supply concerns.

11.09.2026 г., 20:08 ч. UTC

Social Media

10X Genomics Inc. is rising today, supported by positive social media sentiment and strong trading momentum above key moving averages.

10.09.2026 г., 23:26 ч. UTC

10X Genomics shares advanced in after-market trading, remaining above their 20-day moving average and near the upper end of their one-month range.

9.09.2026 г., 19:56 ч. UTC

Social Media
News

UBS raised its price target for 10X Genomics to $68, maintaining a Neutral rating. The stock is trading higher amid positive social media discussions.

8.09.2026 г., 20:07 ч. UTC

News

10X Genomics raises 2026 revenue guidance to $610 million-$630 million, driving shares higher during trading. Analysts express concerns about potential overvaluation.

2.09.2026 г., 20:08 ч. UTC

10X Genomics Inc. shares are higher today, driven by significant gains in the Life Sciences Tools & Services sub-sector. No specific company news was identified.

1.09.2026 г., 20:04 ч. UTC

News

10X Genomics Inc shares are lower after RBC Capital initiated coverage with a Sector Perform rating and a $70 price target. Rising oil prices add to inflation concerns.

31.08.2026 г., 20:07 ч. UTC

News

10X Genomics awarded over $4.8 million in damages by jury for patent infringement. Analysts see potential for favorable outcomes, boosting shares higher today.

28.08.2026 г., 23:46 ч. UTC

10X Genomics Inc is trading higher in after-market hours, reflecting positive market performance amid rising Treasury yields and increased rate hike expectations.

26.08.2026 г., 19:36 ч. UTC

10X Genomics Inc shares are lower today, reaching a session low earlier. Broader inflation data may impact Federal Reserve policy decisions.

25.08.2026 г., 23:21 ч. UTC

10X Genomics Inc shares are higher in after-market hours, though no specific news was identified. Market sentiment improved amid a decline in crude oil prices.

24.08.2026 г., 19:26 ч. UTC

Social Media

10X Genomics Inc shares are lower today amid broader market declines and geopolitical tensions, though the stock remains significantly above its 20-day moving average.

21.08.2026 г., 23:16 ч. UTC

10X Genomics Inc. shares are higher in after-market trading, continuing gains since Friday's close, amid broader cryptocurrency market strength.

20.08.2026 г., 23:16 ч. UTC

10X Genomics Inc. shares traded lower after-market, amid broader market pressure from rising bond yields and concerns over high borrowing costs and geopolitical risks.

19.08.2026 г., 23:06 ч. UTC

10X Genomics Inc shares are higher in after-market trading, reflecting strong momentum above the 20-day moving average and near the top of its one-month range.

18.08.2026 г., 23:31 ч. UTC

10X Genomics Inc shares are higher in after-market trading, maintaining a notable increase while staying above the 20-day moving average. No specific news was identified.

17.08.2026 г., 19:16 ч. UTC

10X Genomics Inc shares are higher today, recovering from an initial dip. The stock remains above its 20-day moving average amid mixed economic indicators.

14.08.2026 г., 20:06 ч. UTC

10X Genomics Inc shares are lower today amid mixed market sentiment following a reported decline in U.S. retail sales for July.

13.08.2026 г., 19:16 ч. UTC

News

10X Genomics Inc reported Q2 revenue of $151 million, exceeding estimates. Shares are higher as management raises full-year revenue guidance to $620 million.

12.08.2026 г., 19:46 ч. UTC

10X Genomics Inc. shares are lower today, having retraced from an early peak. The stock remains above its 20-day moving average.

11.08.2026 г., 20:06 ч. UTC

10X Genomics Inc. shares are lower today amid routine trading, despite earlier fluctuations and remaining above the 20-day moving average.

10.08.2026 г., 20:03 ч. UTC

News
Social Media
Correlated Moves

10X Genomics shares rise as Piper Sandler and Canaccord Genuity raise price targets to $47.00 and $60.00, respectively, amid increased trading volume.

7.08.2026 г., 23:16 ч. UTC

News

10X Genomics Inc shares are lower in after-market trading amid a sector decline. Citigroup raised its price target to $50 while maintaining a Neutral rating.

6.08.2026 г., 23:02 ч. UTC

News

10X Genomics reported a net loss of $17.9 million for Q2, with shares trading lower in after-market hours amid concerns over an operating loss.

5.08.2026 г., 19:26 ч. UTC

Correlated Moves
News

10X Genomics Inc shares are lower amid broader market declines. The company reported $150.8 million in revenue last quarter, reflecting a year-on-year decline.

3.08.2026 г., 19:36 ч. UTC

Correlated Moves
Social Media

10X Genomics Inc reached a new 52-week high, reflecting strong market activity and positive sentiment in the genomics sector. Shares are higher since Friday's close.

31.07.2026 г., 19:36 ч. UTC

Correlated Moves
Social Media

10X Genomics shares are lower today, continuing a decline since Thursday's close. The Russell 2000 Index also reflects broader market weakness.

30.07.2026 г., 17:06 ч. UTC

Correlated Moves

10X Genomics Inc is higher today, supported by broader market trends and a significant rise since Wednesday's close. The stock peaked intraday with notable gains.

29.07.2026 г., 19:27 ч. UTC

Macro Event
News

10X Genomics Inc announced a collaboration with Lausanne University Hospital to enhance cancer diagnostics. Shares are higher since Tuesday's close, reflecting positive sentiment.

Сравнение с други в отрасъла

Ценова промяна

10X Genomics Inc (Class A) Прогноза

Ценова цел

By TipRanks

-28.44% надолу

12-месечна прогноза

Среден 53.231 USD  -28.44%

Висок 70 USD

Нисък 40 USD

Според 15 анализатори от Wall Street, предложили 12-месечна ценова цел за 10X Genomics Inc (Class A) през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

15 ratings

6

Купи

9

Задържане

0

Продай

Настроение

By Acuity

129 / 339 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Среден

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
help-icon Live chat